Who owns the patients, at least in France?

This is a very, very important question because I know it is one of the fastest growing procedures in the USA, two digits per year.

for the last two years, so it's very impressive in the US.

And in Europe, we have been initially influenced by the negative trial that was Omboprotect, that was using particles.

And more recently now, with all the Onyx trials being positive, the Canadian one, the US one, and the latest, the French one, Otemax, that is the first European trial positive for embolic agent, Otemax, very strongly positive.

in favor of treating patients in combination with surgery to avoid recurrence.

So now, since we have this big push, I would say the growth is there.

Would you mind just taking us through a bread and butter and an AMBO from access to authorization, just so the audience gets a sense of what day-to-day operation